


 Substitute Form PTO-1449  
(Modified)

 U.S. Department of Commerce  
Patent and Trademark Office

 Attorney's Docket No.  
20750-044US1

 Application No.  
10/561,101

**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

 Applicant  
Brian Smith, et al.

 Filing Date  
December 16, 2005

 Group Art Unit  
1624

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	7,232,823	6/19/2007	Carpino et al.			
	AB	7,230,024	6/12/2007	Carpino et al.			
	AC	7,230,002	6/12/2007	Thomas et al.			
	AD	7,229,991	6/12/2007	Merla et al.			
	AE	7,227,027	6/5/2007	Qiu et al.			
	AF	7,211,591	5/1/2007	Tajima et al.			
	AG	7,157,466	1/2/2007	McClure et al.			
	AH	7,173,037	2/6/2007	Alonso-Aliza et al.			
	AI	7,105,523	9/12/2006	Stasch et al.			
	AJ						
	AK						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AQ	Bos et al., "Novel Agonists of 5HT <sub>2C</sub> Receptors. Synthesis and Biological Evaluation of Substituted 2-(Indol-1-yl)-1-methylethylamines and 2-(Indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved Therapeutics for Obsessive Compulsive Disorder," J. Med. Chem., Vol. 40, pp. 2762-2769 (1997).
	AR	Cryan et al., "Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine <sub>2C</sub> Receptors," The Journal of Pharmacology and Experimental Therapeutics, Vol. 295, No. 3, pp. 1120-1126 (2000).

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-044US1	Application No. 10/561,101
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Brian Smith, et al.	
		Filing Date December 16, 2005	Group Art Unit 1624

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AS	Grottick et al., "Studies to Investigate the Role of 5-HT <sub>2C</sub> Receptors on Cocaine- and Food-Maintained Behavior <sup>1</sup> ," The Journal of Pharmacology and Experimental Therapeutics, Vol. 295, No. 3, pp. 1183-1191, (2000).
	AT	Guillory, K. "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids," in: Polymorphism in Pharmaceutical Solids, ed. Harry G. Brittan, Vol. 95, pp.202-209, Marcel Dekker, Inc., New York, (1999).
	AU	Martin et al., "5-HT <sub>2C</sub> Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential," The Journal of Pharmacology and Experiment Therapeutics, Vol. 286, No. 2, pp. 913-924 (1998).
	AV	Morissette et al., "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids," Advanced Drug Delivery Reviews, Vol. 56, pp. 275-300 (2004).
	AW	Vippagunta et al., "Crystalline solids," Advanced Drug Delivery Reviews, Vol. 48, pp. 3-26 (2001).
	AX	West et al., "Solid State Chemistry and its Applications," pp. 1-3; 358-373 (1984).
	AY	Wood et al., "5-HT <sub>2C</sub> Receptor Antagonists: Potential in Schizophrenia," Drug Development Research, Vol. 58, pp. 88-94 (2001).

Examiner Signature	Date Considered
<b>EXAMINER:</b> Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	